Evidence map›Paper›PMID 40144622›Full record

ArticleFrontiers in neurology2025

Nef is a key player in neuroinflammation and myelin impairment associated with neuroHIV.

Michael Ilya Bukrinsky

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael Ilya BukrinskySchool of Medicine and Health Sciences, The George Washington University, Washington, DC, United States.

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
Supplement to R01 NS124477R01NS124477 · NINDS · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, TYOR, WILLIAM R · 2021 to 2025
$3.6M
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous systemR01MH128158 · NIMH · EMORY UNIVERSITY · PI Christina Gavegnano, Vincent Charles Marconi · 2022 to 2026
$3.2M
Lipid raft therapy – a novel therapeutic approach for HIV-associated cardiometabolic co-morbiditiesR01HL158305 · NHLBI · GEORGE WASHINGTON UNIVERSITY · PI BUKRINSKY, MICHAEL ILYA, SVIRIDOV, DMITRI · 2021 to 2024
$2.6M
NHLBI NIH HHS R01 HL158305NIAID NIH HHS P30 AI117970NIMH NIH HHS R01 MH128158NINDS NIH HHS R01 NS124477
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

human immunodeficiency virus (HIV)inflammationmyelin alterationNef + exosomesneuroHIV

Identifiers

PMID40144622
PMCPMC11936826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.